These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3754811)

  • 1. [Results with the use of the M-2 protocol in plasmacytoma].
    Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
    Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polychemotherapy in multiple myeloma. The COMPA protocol].
    Vázquez-Villegas V; Delgado Lamas JL; Romero-García F; Rodríguez-Carrillo J; Medina-Ruiz F
    Rev Invest Clin; 1989; 41(4):345-50. PubMed ID: 2698501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
    Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
    Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
    Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
    [No Abstract]   [Full Text] [Related]  

  • 9. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
    Kyle RA; Leong T; Li S; Oken MM; Kay NE; Van Ness B; Greipp PR
    Cancer; 2006 May; 106(9):1958-66. PubMed ID: 16565956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
    J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
    Steinke B; Busch FW; Stapelfeld S; Ostendorf P; Waller HD
    Dtsch Med Wochenschr; 1984 Jun; 109(26):1015-9. PubMed ID: 6547386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
    Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
    Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chemotherapy of multiple myeloma].
    Golenkov AK
    Sov Med; 1991; (3):43-6. PubMed ID: 1882290
    [No Abstract]   [Full Text] [Related]  

  • 14. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
    Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
    Wutke K; Anger G
    Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
    Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
    Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
    Kraj M; Dmoszyńska A; Maj S; Kowalewski J; Rostkowska J; Pogłód R; Sokołowska B; Mendek-Czajkowska E; Kurowska M; Sokołowska U
    Acta Haematol Pol; 1991; 22(1):4-20. PubMed ID: 1823965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.